Compare Charles River Laboratories Intl. Inc (CRL) vs T-Rex 2X Long MSTR Daily Target ETF (MSTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs T-Rex 2X Long MSTR Daily Target ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $287.43 (market cap $13.46B), while T-Rex 2X Long MSTR Daily Target ETF trades at $1.81. The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals.
| CRL | MSTU | |
|---|---|---|
Market Cap | $13.46B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $284.37 | $74.30 |
52-Week Low | $145.57 | $1.46 |
Enterprise Value | $16.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.
The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.
MSTU is trading at $1.81, down 4.23% today, with a bearish technical outlook showing 15 sell signals versus 1 buy signal. The ETF has experienced significant value erosion, with recent articles highlighting a 98% decline from November 2024 levels. A 10:1 reverse stock split is scheduled for August 2026, reflecting the fund's substantial challenges amid volatile market conditions.
The outlook remains highly risky given the leveraged structure's daily compounding effects and severe historical losses. While potential exists for recovery if underlying assets rebound, the fund's track record suggests continued vulnerability to market volatility. Investors should approach with extreme caution given the documented 95% annual decline and structural risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About T-Rex 2X Long MSTR Daily Target ETF
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →
